Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery exhibited similarly significant benefits in quality of life (QOL) and symptom burden when given an exhalation system with fluticasone.
Significant symptom and quality of life (QOL) improvement was associated with an exhalation system with fluticasone (EDS-FLU) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who are surgery-naive or whose symptoms recur after endoscopic sinus surgery (ESS), according to study findings published in the International Forum of Allergy & Rhinology.
For presurgery and postsurgery patients with CRSwNP, clinical guidelines recommend the use of topically delivered glucocorticoids, despite most patients reporting inadequate symptom relief with the medication.
Using a novel delivery system to create closed-palate, positive-pressure, bidirectional mechanics that significantly alter the deposition of fluticasone, the FDA-approved EDS-FLU (XHANCE) has been shown in prior research to reduce nasal polyp severity in objective and patient-reported measures.
“A question not yet answered is whether results with EDS-FLU differ for patients with surgically altered anatomy,” wrote the authors of the current study. “A recently published consensus treatment algorithm for evidence-based, stepwise management of CRSwNP recommends use of EDS-FLU prior to escalating care to sinus surgery and also as an option for post-surgical medical management, but trial data have not been published separately evaluating unoperated patients vs those with prior surgery.”
They conducted an analysis of pooled symptom, QOL, and polyp grade outcomes data from the NAVIGATE I (NCT01622569) and II (NCT01624662) randomized, controlled, double-blind, 24-week trials to evaluate the efficacy of EDS-FLU in patients with CRSwNP with symptom recurrence after surgery, and to compare results with unoperated patients.
Outcome measures assessed included the mean change from baseline through week 16 in nasal congestion scores, mean change from baseline through week 24 in the Sino-Nasal Outcome Test (SNOT-22 total score and subscales), mean change from baseline in Rhinosinusitis Disability Index (RSDI) total score and subscales at week 16, Patient Global Impression of Change (PGIC) scores at week 16, and mean change from baseline through week 24 in bilaterally summed NP grade.
Of 482 patients included in the analysis, approximately one-third (n = 154) reported a history of sinus surgery at study entry, with the mean number of prior surgeries per patient in the prior-surgery group reported as 1.6.
Patients with prior ESS (EDS-placebo, n = 53; EDS-FLU 186 mcg, n = 52; EDS-FLU 372 mcg, n = 49) and unoperated patients (EDS-placebo, n = 108; EDS-FLU 186 mcg, n = 108; EDS-FLU 372 mcg, n = 111) treated with EDS-FLU reported similar and significant benefits at 16 weeks in mean congestion scores, mean RSDI total score, and PGIC, and at 24 weeks in SNOT-22 and NP grade.
Notably, multiple outcomes (SNOT-22, RSDI, polyp grade) consistently showed numerically but not statistically greater responses to the higher dose of EDS-FLLU in previously operated patients, which was not found in surgery-naive patients.
“Considering risk and benefit, EDS-FLU is an important therapeutic option, particularly for patients without adequate response to standard topical nasal steroids, at several points in a stepwise care algorithm, including as medical therapy prior to sinus surgery, and for maintenance treatment or recurrent symptoms following surgery,” the researchers concluded.
Reference
Ow RA, Soler ZM, Sindwani R, et al. Efficacy of the exhalation delivery system with fluticasone (EDS-FLU) in patients with chronic rhinosinusitis with nasal polyps whose symptoms recur after sinus surgery. Int Forum Allergy Rhinol. Published online June 8, 2022. doi:10.1002/alr.23043
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More